-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Biogen, Lowers Price Target to $255

Benzinga·05/02/2025 12:26:53
Listen to the news
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $300 to $255.